U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C13H10O3
Molecular Weight 214.2167
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PHENYL SALICYLATE

SMILES

OC1=C(C=CC=C1)C(=O)OC2=CC=CC=C2

InChI

InChIKey=ZQBAKBUEJOMQEX-UHFFFAOYSA-N
InChI=1S/C13H10O3/c14-12-9-5-4-8-11(12)13(15)16-10-6-2-1-3-7-10/h1-9,14H

HIDE SMILES / InChI
Molecular Formula C13H10O3
Molecular Weight 214.2167
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/23387858

Phenyl salicylate belongs to the family of hydroxybenzoic acid derivatives. Phenyl salicylate is used as a food additive. Antimycobacterial activity of phenyl salicylates (salols) was studied in connection with antituberculotic activity of salicylic derivatives. Phenyl salicylates are esters. Phenyl salicylates (salols) represent a new group of antimycobacterial compounds. Phenyl salicylate is included in the number of medications, indicated for the treatment of symptoms of irritative voiding, used to relieve the discomfort, pain, frequent urge to urinate, and cramps/spasms of the urinary tract caused by an infection or a medical procedure. Phenyl salicylate works as a pain reliever in these combinations.

Originator

Approval Year

1921
1467
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2678
 49.78 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
PROSED EC

Approved Use

PROSED EC is indicated for the relief of discomfort of the lower urinary tract caused by hypermotility resulting from inflammation or diagnostic procedures and in the treatment of cystitis, urethritis and trigonitis when caused by organisms which maintain or produce an acid urine and are susceptible to formaldehyde.
PubMed

PubMed

TitleDatePubMed
Estrogenic activity of phenolic additives determined by an in vitro yeast bioassay.
2001 Feb
Effect of some ultraviolet light absorbers on photo-stabilization of azadirachtin-A.
2002 Oct
Effect of ultraviolet light absorbers on photostabilization of azadirachtin-A in solution (part: II).
2003 Jan
Viscosity at the dynamic crossover in o-terphenyl and salol under high pressure.
2004 Jun 18
Prediction of estrogen receptor agonists and characterization of associated molecular descriptors by statistical learning methods.
2006 Nov
Mass spectrometric identification of covalent adducts of the skin allergen 2,4-dinitro-1-chlorobenzene and model skin proteins.
2008 Aug
Kinetic evidence for the occurrence of independent ion-exchange processes in the cationic micellar-mediated reaction of piperidine with anionic phenyl salicylate.
2009 Jun 11
The role of nucleation in vitrification of supercooled liquids.
2010 Apr 21
Infrared spectroscopy study of structural changes in glass-forming salol.
2010 Mar
Phenyl 3,5-di-tert-butyl-2-hy-droxy-benzoate.
2010 Nov 24
The estrogenic potential of salicylate esters and their possible risks in foods and cosmetics.
2012 Mar 7
Simultaneous determination of the UV-filters benzyl salicylate, phenyl salicylate, octyl salicylate, homosalate, 3-(4-methylbenzylidene) camphor and 3-benzylidene camphor in human placental tissue by LC-MS/MS. Assessment of their in vitro endocrine activity.
2013 Oct 1
Patents

Patents

JP2000044925A
2
JP2000159880A
1
JP2000159963A
1
JPH0328248A
2
JPH06166602A
1
JPH07177826A
1
JPS56118424A
1
JPS59206452A
2
JPS5951232A
1
JPS61115950A
1

Sample Use Guides

In Vivo Use Guide
One tablet of PROSED EC orally 4 times per day followed by liberal fluid intake. Each tablet of PROSED EC contains: Phenyl Salicylate 36.2 mg
Route of Administration: Oral
In Vitro Use Guide
Phenyl Salicylate at 10 uM increased the number of MCF-7 cells by approximately 1.8 fold
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:45:01 UTC 2023
Edited
by admin
on Fri Dec 15 16:45:01 UTC 2023
Record UNII
28A37T47QO
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PHENYL SALICYLATE
FHFI   INCI   MI   VANDF   WHO-DD  
INCI  
Official Name English
PHENYL SALICYLATE [VANDF]
Common Name English
PHENYL SALICYLATE [INCI]
Common Name English
PHENYL SALICYLATE [USP-RS]
Common Name English
Phenyl salicylate [WHO-DD]
Common Name English
FEMA NO. 3960
Code English
PHENYL SALICYLATE MELTING POINT STANDARD
USP-RS  
Common Name English
SALOL [HPUS]
Common Name English
PHENYL SALICYLATE [FHFI]
Common Name English
PHENYL SALICYLATE [MI]
Common Name English
SALOL
HPUS   MART.   VANDF  
Common Name English
NSC-33406
Code English
SALOL [MART.]
Common Name English
SALOL [VANDF]
Common Name English
Classification Tree Code System Code
JECFA EVALUATION PHENYL SALICYLATE
Created by admin on Fri Dec 15 16:45:01 UTC 2023 , Edited by admin on Fri Dec 15 16:45:01 UTC 2023
WHO-VATC QG04BX12
Created by admin on Fri Dec 15 16:45:01 UTC 2023 , Edited by admin on Fri Dec 15 16:45:01 UTC 2023
WHO-ATC G04BX12
Created by admin on Fri Dec 15 16:45:01 UTC 2023 , Edited by admin on Fri Dec 15 16:45:01 UTC 2023
NCI_THESAURUS C2356
Created by admin on Fri Dec 15 16:45:01 UTC 2023 , Edited by admin on Fri Dec 15 16:45:01 UTC 2023
Code System Code Type Description
NCI_THESAURUS
C75079
Created by admin on Fri Dec 15 16:45:01 UTC 2023 , Edited by admin on Fri Dec 15 16:45:01 UTC 2023
PRIMARY
EPA CompTox
DTXSID6021957
Created by admin on Fri Dec 15 16:45:01 UTC 2023 , Edited by admin on Fri Dec 15 16:45:01 UTC 2023
PRIMARY
MERCK INDEX
m8690
Created by admin on Fri Dec 15 16:45:01 UTC 2023 , Edited by admin on Fri Dec 15 16:45:01 UTC 2023
PRIMARY Merck Index
JECFA MONOGRAPH
607
Created by admin on Fri Dec 15 16:45:01 UTC 2023 , Edited by admin on Fri Dec 15 16:45:01 UTC 2023
PRIMARY
ECHA (EC/EINECS)
204-259-2
Created by admin on Fri Dec 15 16:45:01 UTC 2023 , Edited by admin on Fri Dec 15 16:45:01 UTC 2023
PRIMARY
WIKIPEDIA
PHENYL SALICYLATE
Created by admin on Fri Dec 15 16:45:01 UTC 2023 , Edited by admin on Fri Dec 15 16:45:01 UTC 2023
PRIMARY
RS_ITEM_NUM
1534209
Created by admin on Fri Dec 15 16:45:01 UTC 2023 , Edited by admin on Fri Dec 15 16:45:01 UTC 2023
PRIMARY
DAILYMED
28A37T47QO
Created by admin on Fri Dec 15 16:45:01 UTC 2023 , Edited by admin on Fri Dec 15 16:45:01 UTC 2023
PRIMARY
ChEMBL
CHEMBL1339216
Created by admin on Fri Dec 15 16:45:01 UTC 2023 , Edited by admin on Fri Dec 15 16:45:01 UTC 2023
PRIMARY
RXCUI
895808
Created by admin on Fri Dec 15 16:45:01 UTC 2023 , Edited by admin on Fri Dec 15 16:45:01 UTC 2023
ALTERNATIVE
MESH
C026041
Created by admin on Fri Dec 15 16:45:01 UTC 2023 , Edited by admin on Fri Dec 15 16:45:01 UTC 2023
PRIMARY
CHEBI
34918
Created by admin on Fri Dec 15 16:45:01 UTC 2023 , Edited by admin on Fri Dec 15 16:45:01 UTC 2023
PRIMARY
DRUG CENTRAL
3462
Created by admin on Fri Dec 15 16:45:01 UTC 2023 , Edited by admin on Fri Dec 15 16:45:01 UTC 2023
PRIMARY
EVMPD
SUB14839MIG
Created by admin on Fri Dec 15 16:45:01 UTC 2023 , Edited by admin on Fri Dec 15 16:45:01 UTC 2023
PRIMARY
FDA UNII
28A37T47QO
Created by admin on Fri Dec 15 16:45:01 UTC 2023 , Edited by admin on Fri Dec 15 16:45:01 UTC 2023
PRIMARY
RXCUI
36122
Created by admin on Fri Dec 15 16:45:01 UTC 2023 , Edited by admin on Fri Dec 15 16:45:01 UTC 2023
PRIMARY
DRUG BANK
DB11071
Created by admin on Fri Dec 15 16:45:01 UTC 2023 , Edited by admin on Fri Dec 15 16:45:01 UTC 2023
PRIMARY
PUBCHEM
8361
Created by admin on Fri Dec 15 16:45:01 UTC 2023 , Edited by admin on Fri Dec 15 16:45:01 UTC 2023
PRIMARY
CAS
118-55-8
Created by admin on Fri Dec 15 16:45:01 UTC 2023 , Edited by admin on Fri Dec 15 16:45:01 UTC 2023
PRIMARY
SMS_ID
100000079433
Created by admin on Fri Dec 15 16:45:01 UTC 2023 , Edited by admin on Fri Dec 15 16:45:01 UTC 2023
PRIMARY
NSC
33406
Created by admin on Fri Dec 15 16:45:01 UTC 2023 , Edited by admin on Fri Dec 15 16:45:01 UTC 2023
PRIMARY
Related Record Type Details
Structure of PHENYL SALICYLATE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966